Abstract: The present application provides a level shift circuit, an integrated circuit, and an electronic device. The level shift circuit comprises: an input module, configured to output a first control signal according to a first power supply voltage signal, first and second input voltages, inverted voltages of the first and second input voltages that received; a control voltage generation module, configured to receive the first control signal, and generate a plurality of node voltages according to the first control signal and a second power supply voltage signal; and output control modules, configured to generate first to fourth output signals according to the second power supply voltage signal and the node voltages.

Abstract: The present application provides a level shift circuit, an integrated circuit, and an electronic device. The level shift circuit comprises: an input module, configured to output a first control signal according to a first power supply voltage signal, first and second input voltages, inverted voltages of the first and second input voltages that received; a control voltage generation module, configured to receive the first control signal, and generate a plurality of node voltages according to the first control signal and a second power supply voltage signal; and output control modules, configured to generate first to fourth output signals according to the node voltages and the first power supply voltage signal, or generate fifth to eighth output signals according to the second power supply voltage signal and the node voltages.

Abstract: The present application provides a level shift circuit, an integrated circuit, and an electronic device. The level shift circuit comprises: an input module, configured to output a first control signal according to a first power supply voltage signal, first and second input voltages, inverted voltages of the first and second input voltages that received; a control voltage generation module, configured to receive the first control signal, and generate a plurality of node voltages according to the first control signal and a second power supply voltage signal; and output control modules, configured to generate first to fourth output signals according to the node voltages and the first power supply voltage signal, or generate fifth to eighth output signals according to the second power supply voltage signal and the node voltages.

Abstract: The present invention provides novel processes for the preparation of regadenoson having the formula (I). In some embodiments, the intermediates for the synthesis of regadenoson are also provided.

Abstract: A concise, efficient and cost- and time-saving process for the preparation of a quinazoline derivative of formula A given below: which is an intermediate for making gefitinib or gefitinib itself, comprising reacting a compound of Formula B: with 3-chloro-4-fluoroaniline (VI) in the presence of a N,N-dialkyl formamide acetal, a Bronsted acid catalyst, and a solvent in a one-pot reaction.

Abstract: The present invention provides novel processes for the preparation of regadenoson having the formula (I). In some embodiments, the intermediates for the synthesis of regadenoson are also provided.

Abstract: A concise, efficient and cost- and time-saving process for the preparation of a quinazoline derivative of formula A given below: which is an intermediate for making gefitinib or gefitinib itself, comprising reacting a compound of Formula B: with 3-chloro-4-fluoroaniline (VI) in the presence of a N,N-dialkyl formamide acetal, a Bronsted acid catalyst, and a solvent in a one-pot reaction.

Abstract: A compound of formula (X): which can be used as an intermediate to make lapatinib or its pharmaceutically acceptable salt.

Abstract: A process for making clofarabine comprising: fluorinating a compound of formula VII wherein each R4 is independently a hydroxy protecting group, OR6 is a leaving group, with a fluorinating agent in the presence of guanidine carbonate to give a compound of formula VIII: wherein R4 is as defined above; and deprotecting the compound of formula VIII to give the clofarabine.

Abstract: A compound of formula (X): which can be used as an intermediate to make lapatinib or its pharmaceutically acceptable salt.

Abstract: A method for producing a ?-enriched protected decitabine comprising: a) coupling a protected 2-deoxy-ribofuranose with a protected 5-azacytosine in the presence of a catalyst to form a reaction mixture comprising the protected decitabine of formula I; and b) quenching the reaction mixture of step a) with a base. The ?-enriched protected decitabine so made may be deprotected to produce a decitabine product in a high yield and purity.

Abstract: The present invention provides a process for making lapatinib and its pharmaceutically acceptable salt by use of new intermediates. A new process for obtaining a pharmaceutical form of lapatinib ditosylate monohydrate is also provided.

Abstract: The present invention provides a process for making lapatinib and its pharmaceutically acceptable salt by use of new intermediates. A new process for obtaining a pharmaceutical form of lapatinib ditosylate monohydrate is also provided.

Abstract: A method of making cladribine with an increased purity comprising: a) dissolving crude cladribine in a protic solvent in the presence of a base to form a solution comprising dissolved crude cladribine; b) maintaining the solution at an elevated temperature so that the solution is homogeneous until the amount of protected or partially protected nucleoside impurities in the solution is reduced to a pre-determined upper limit; and c) cooling the solution of step b) so that crystals of cladribine are formed and isolated.

Abstract: A method of making cladribine with an increased purity comprising: a) dissolving crude cladribine in a protic solvent in the presence of a base to form a solution comprising dissolved crude cladribine; b) maintaining the solution at an elevated temperature so that the solution is homogeneous until the amount of protected or partially protected nucleoside impurities in the solution is reduced to a pre-determined upper limit; and c) cooling the solution of step b) so that crystals of cladribine are formed and isolated.

Abstract: A process for the preparation of cladribine of API grade is provided by direct coupling of O-protected 2-deoxy-ribofuranose with silylated 2-chloroadenine followed by deprotection of the resultant protected nucleoside in a separate step and then a purification step. Following the coupling, the desired N-9-glycosylated ?-anomer of the nucleoside is directly isolated as a solid from the coupling reaction mixture by filtration in relatively high purity and yield, and it does not require purification.

Abstract: A process of synthesizing a 5-azacytosine nucleoside, such as azacitidine and decitabine, comprises coupling a silylated 5-azacytosine with a protected D-ribofuranose of formula in the presence of a sulfonic acid catalyst.

Abstract: A process for making clofarabine comprising: fluorinating a compound of formula VII wherein each R4 is independently a hydroxy protecting group, OR6 is a leaving group, with a fluorinating agent in the presence of guanidine carbonate to give a compound of formula VIII: wherein R4 is as defined above; and deprotecting the compound of formula VIII to give the clofarabine.

Abstract: A process for the preparation of cladribine of API grade is provided by direct coupling of O-protected 2-deoxy-ribofuranose with silylated 2-chloroadenine followed by deprotection of the resultant protected nucleoside in a separate step and then a purification step. Following the coupling, the desired N-9-glycosylated ?-anomer of the nucleoside is directly isolated as a solid from the coupling reaction mixture by filtration in relatively high purity and yield, and it does not require purification.

Abstract: A method for producing a ?-enriched protected decitabine comprising: a) coupling a protected 2-deoxy-ribofuranose with a protected 5-azacytosine in the presence of a catalyst to form a reaction mixture comprising the protected decitabine of formula I; and b) quenching the reaction mixture of step a) with a base. The ?-enriched protected decitabine so made may be deprotected to produce a decitabine product in a high yield and purity.